Liabilities, Current in USD of Anixa Biosciences Inc from Q3 2010 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Summary
Anixa Biosciences Inc quarterly Liabilities, Current history and change rate from Q3 2010 to Q2 2025.
  • Anixa Biosciences Inc Liabilities, Current for the quarter ending 31 Jul 2025 was $2.07M, a 3.09% increase year-over-year.
Liabilities, Current, Quarterly (USD)
Liabilities, Current, YoY Quarterly Change (%)

Anixa Biosciences Inc Quarterly Liabilities, Current (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2025 $2.07M +$62K +3.09% 31 Jul 2025 10-Q 10 Sep 2025
Q1 2025 $1.89M +$206K +12.3% 30 Apr 2025 10-Q 28 May 2025
Q4 2024 $2M +$339K +20.4% 31 Jan 2025 10-Q 11 Mar 2025
Q3 2024 $2.5M +$472K +23.3% 31 Oct 2024 10-Q 10 Sep 2025
Q2 2024 $2M +$147K +7.92% 31 Jul 2024 10-Q 06 Sep 2024
Q1 2024 $1.68M +$144K +9.37% 30 Apr 2024 10-Q 04 Jun 2024
Q4 2023 $1.66M +$428K +34.7% 31 Jan 2024 10-Q 12 Mar 2024
Q3 2023 $2.03M -$9K -0.44% 31 Oct 2023 10-K 10 Jan 2025
Q2 2023 $1.86M +$388K +26.4% 31 Jul 2023 10-Q 06 Sep 2023
Q1 2023 $1.54M +$348K +29.3% 30 Apr 2023 10-Q 14 Jun 2023
Q4 2022 $1.23M -$555K -31.1% 31 Jan 2023 10-Q 17 Mar 2023
Q3 2022 $2.04M +$767K +60.4% 31 Oct 2022 10-K 16 Jan 2024
Q2 2022 $1.47M +$261K +21.6% 31 Jul 2022 10-Q 09 Sep 2022
Q1 2022 $1.19M -$254K -17.6% 30 Apr 2022 10-Q 10 Jun 2022
Q4 2021 $1.79M +$262K +17.1% 31 Jan 2022 10-Q 11 Mar 2022
Q3 2021 $1.27M +$81.4K +6.85% 31 Oct 2021 10-K 04 Jan 2023
Q2 2021 $1.21M -$5.18K -0.43% 31 Jul 2021 10-Q 01 Sep 2021
Q1 2021 $1.44M +$366K +34% 30 Apr 2021 10-Q 10 Jun 2021
Q4 2020 $1.53M +$400K +35.5% 31 Jan 2021 10-Q 11 Mar 2021
Q3 2020 $1.19M -$293K -19.8% 31 Oct 2020 10-K 04 Jan 2022
Q2 2020 $1.21M -$230K -16% 31 Jul 2020 10-Q 08 Sep 2020
Q1 2020 $1.08M -$519K -32.5% 30 Apr 2020 10-Q 09 Jun 2020
Q4 2019 $1.13M -$202K -15.2% 31 Jan 2020 10-Q 09 Mar 2020
Q3 2019 $1.48M +$216K +17.1% 31 Oct 2019 10-K 07 Jan 2021
Q2 2019 $1.44M +$314K +27.8% 31 Jul 2019 10-Q 06 Sep 2019
Q1 2019 $1.6M +$256K +19.1% 30 Apr 2019 10-Q 12 Jun 2019
Q4 2018 $1.33M +$241K +22.1% 31 Jan 2019 10-Q 13 Mar 2019
Q3 2018 $1.27M +$376K +42.2% 31 Oct 2018 10-K 09 Jan 2020
Q2 2018 $1.13M -$1.8M -61.4% 31 Jul 2018 10-Q 07 Sep 2018
Q1 2018 $1.34M -$2.32M -63.4% 30 Apr 2018 10-Q 11 Jun 2018
Q4 2017 $1.09M -$2.64M -70.8% 31 Jan 2018 10-Q 09 Mar 2018
Q3 2017 $889K +$421K +89.8% 31 Oct 2017 10-K 11 Jan 2019
Q2 2017 $2.93M +$2.4M +451% 31 Jul 2017 10-Q 08 Sep 2017
Q1 2017 $3.66M +$2.95M +418% 30 Apr 2017 10-Q 26 May 2017
Q4 2016 $3.72M +$2.48M +199% 31 Jan 2017 10-Q 16 Mar 2017
Q3 2016 $469K -$125K -21.1% 31 Oct 2016 10-K 09 Jan 2018
Q2 2016 $532K -$180K -25.3% 31 Jul 2016 10-Q 19 Aug 2016
Q1 2016 $707K +$18.3K +2.65% 30 Apr 2016 10-Q 20 May 2016
Q4 2015 $1.24M -$423K -25.4% 31 Jan 2016 10-Q 19 Feb 2016
Q3 2015 $594K -$1.22M -67.2% 31 Oct 2015 10-K 08 Dec 2016
Q2 2015 $712K -$7.65M -91.5% 31 Jul 2015 10-Q 18 Aug 2015
Q1 2015 $689K -$9.99M -93.6% 30 Apr 2015 10-Q 22 May 2015
Q4 2014 $1.67M -$9.88M -85.6% 31 Jan 2015 10-Q 09 Mar 2015
Q3 2014 $1.81M -$1.4M -43.7% 31 Oct 2014 10-K 23 Dec 2015
Q2 2014 $8.36M +$5.26M +170% 31 Jul 2014 10-Q 15 Sep 2014
Q1 2014 $10.7M +$7.38M +224% 30 Apr 2014 10-Q 16 Jun 2014
Q4 2013 $11.5M +$8.11M +236% 31 Jan 2014 10-Q 17 Mar 2014
Q3 2013 $3.21M +$1.39M +76.2% 31 Oct 2013 10-K 29 Jan 2015
Q2 2013 $3.09M +$1.31M +73.9% 31 Jul 2013 10-Q/A 20 Sep 2013
Q1 2013 $3.3M +$1.17M +54.8% 30 Apr 2013 10-Q/A 19 Jun 2013
Q4 2012 $3.44M +$1.38M +67.3% 31 Jan 2013 10-Q/A 25 Mar 2013
Q3 2012 $1.82M -$283K -13.4% 31 Oct 2012 10-K/A 17 Jan 2014
Q2 2012 $1.78M -$1.15M -39.2% 31 Jul 2012 10-Q 14 Sep 2012
Q1 2012 $2.13M 30 Apr 2012 10-Q 14 Jun 2012
Q4 2011 $2.06M 31 Jan 2012 10-Q 16 Mar 2012
Q3 2011 $2.11M +$1.66M +368% 31 Oct 2011 10-K 29 Jan 2013
Q2 2011 $2.93M 31 Jul 2011 10-Q/A 14 Oct 2011
Q3 2010 $450K 31 Oct 2010 10-K 30 Jan 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.